10 terminated. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 10 |
| Phase 2 | 5 | Terminated 5 |
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 2 | 2019-04-10 | 2025-07-09 |
| Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT LDE225 - Graft Versus Host Disease | Phase 1 | Terminated | Massachusetts General Hospital | 17 | 2014-04-01 | 2018-03-19 |
| In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus - Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Hackensack Meridian Health | 3 | 2011-08-01 | 2026-04-08 |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation - Graft Versus Host Disease, Leukemia | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2008-06-01 | 2017-11-29 |
| Rapamycin for Prevention of Chronic Graft-Versus-Host Disease Rapamycin, Tacrolimus - Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Yale University | 2 | 2008-02-01 | 2017-02-03 |
| Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer alemtuzumab, busulfan, cyclophosphamide - Graft Versus Host Disease, Leukemia | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2007-09-01 | 2017-05-24 |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases cyclophosphamide, cyclosporine, fludarabine phosphate - Graft Versus Host Disease, Leukemia | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2007-05-01 | 2017-12-02 |
| Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Opebacan - Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | XOMA (US) LLC | 6 | 2007-02-01 | 2012-07-30 |
| Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease Everolimus - Graft Versus Host Disease | Phase 1 | Terminated | University Hospital Tuebingen | 10 | 2006-09-01 | 2014-05-29 |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Fludarabine, Melphalan, Campath - Preleukemia, Myeloproliferative Disorders | Phase 1 | Terminated | University of Chicago | 1 | 2003-05-01 | 2014-03-17 |
Graft vs Host Disease (10) · Leukemia (3) · Lymphoma (3) · Myelodysplastic Syndromes (3) · Neoplasms, Plasma Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Congenital Abnormalities (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2)
Immune System Diseases (10) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Bone Marrow Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, Lymphoid (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Pathologic Processes (3)
Cyclophosphamide (3) · Alemtuzumab (2) · Sirolimus (2) · Tacrolimus (2) · Azacitidine (1) · Busulfan (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Everolimus (1) · Interleukin-2 (1) · Melphalan (1) · Methotrexate (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1) · Transplantation (1)
Masonic Cancer Center, University of Minnesota (2) · Centre Hospitalier Universitaire de Besancon (1) · Fred Hutchinson Cancer Center (1) · Hackensack Meridian Health (1) · Massachusetts General Hospital (1) · University Hospital Tuebingen (1) · University of Chicago (1) · XOMA (US) LLC (1) · Yale University (1)
United States (8) · France (1) · Germany (1)
Andrew Artz, M.D. (1) · Ann E. Woolfrey, MD (1) · Claudio G. Brunstein, MD, PhD (1) · Eva C Guinan, MD (1) · Margaret L. MacMillan, MD (1) · Michele Donato, MD (1) · Stuart Seropian, M.D. (1) · Wolfgang A Bethge, MD (1) · Yi-Bin Chen, MD (1)
P30CA015704 (1)